These results suggest that in addition to regulating leukocyte recruitment and function, SPM may also contribute to reducing the hypercoagulable state observed in patients with COVID-19 by downregulating the expression of CD142 on circulating and tissue-resident phagocytes. The gene discussed is F3; the disease is COVID-19.